The Federal Government has approved the provisional use of an anti-malaria R-21 vaccine. The National Agency for Food and Drug Administration and Control, NAFDAC said the R-21 vaccine by the Serum Institute in India met safety and efficacy criteria, after an evaluation by a Joint Review Committee. The review committee also noted that the vaccine is 75 per cent effective in protecting against malaria.

NAFDAC Director-General, Mojisola Adeyeye, explained that the vaccine’s potential benefits outweigh its known and potential risks, thereby supporting the manufacturer’s recommended use.

She added that the provisional approval of the R-21 malaria vaccine makes Nigeria the second country to approve its use after Ghana.

Adeyeye, also said Nigeria is expected to get at least 100,000 doses of the vaccine in donations soon, to be coordinated by the National Primary Health Care Development Agency, NPHCDA.

The World Health Organisation, WHO, estimate said Malaria is far more deadly than Covid-19 in Africa, saying it had killed 386,000 Africans in 2019.

Leave a Reply